CHINAAMC FRANKLIN FTSE INNOVATIVE DRUGS ETF

CHINAAMC FRANKLIN FTSE INNOVATIVE DRUGS ETF is an investment fund structure domiciled in HONG KONG, Hong Kong SAR China. Funds hold LEIs in their own right, and GLEIF records who manages them rather than who owns them.

The LEI was issued in 2026. That is about 6 years later than the median LEI in Hong Kong SAR China (2020).

The next annual re-validation is due 2 Jul 2027, 236 days from now.

This archive holds 2 versions of the record. The most recent change was on 30 Jul 2026 and altered the legal name; the oldest version we hold dates from 6 Jul 2026. GLEIF publishes only the current state, so superseded values are not available from the source.

The LEI is issued and maintained by LONDON STOCK EXCHANGE LEI LIMITED, one of the Local Operating Units accredited by GLEIF.

No direct accounting-consolidating parent is reported, because no parent prepares consolidated accounts that include it. GLEIF requires this to be stated explicitly rather than left blank, so the absence is itself a data point.

No ultimate accounting-consolidating parent is reported, because no parent prepares consolidated accounts that include it. GLEIF requires this to be stated explicitly rather than left blank, so the absence is itself a data point.

The LEI registration is issued, and the entity status (active) records whether the legal entity itself still exists. The two are independent: an LEI can lapse while the company trades on, and it can stay issued after the company has been dissolved.